Fig. 3From: Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancerABCC3 pharmacological inhibition reduces PDAC progression in in vivo mouse models. Mice were injected with HPAFII cells and treated with 25 mg/kg MCI-715 for 28 days as described in Methods section. Data presents the comparison of the tumour growth (a) and survival (b) of HPAFII xenograft mouse model treated with vehicle (n = 4) and MCI-715 (n = 6), Multiple-t-test was performed for statistical analysis of tumour growth, p = 0.0343, Logrank (Mantel-Cox) was performed for statistical analysis of the survival, p = 0.0033; (c) PDX mouse model was created and treated with 25 mg/kg MCI-715 as described in Methods section. Tumour growth in PDX mouse model of pancreatic cancer treated with vehicle (n = 5) and MCI-715 (n = 5) shows significant difference between the two treatment groups. Arrows indicate start and the end of the treatment period, Multiple-t-test was performed for statistical analysis of tumour growth *p < 0.05; (d) KPC transgenic mouse model was treated with 25 mg/kg MCI-715 as described in Methods section. Kaplan Meier survival curve of KPC mice treated with vehicle (n = 8) and MIC-715 (n = 6). Logrank (Mantel-Cox) test was performed for statistical analysis, p = 0.0010Back to article page